Dr. Yesim Gkmen-Polar

Indiana University School of Medicine Indianapolis, USA

Email: ypolar@iupui.edu

Qualifications

1990 Ph.D., Bogazici University, Molecular Biology

1988 M.Sc., Bogazici University, Molecular Biology

1983 B.Sc., Bogazici University, Biology

Publications (selected)

1. Gökmen-Polar Y*, Sanders KL, Goswami C et al. Establishment and Characterization of a Novel Cell Line Derived from Human Thymoma A/B Tumor. Lab Invest in press (* corresponding author)
2. Badve S, Goswami C, Gökmen-Polar Y et al. Gene Expression Analysis of Thymic Neoplasms. PLoS ONE in press.
3. Gökmen-Polar Y, Badve S. Molecular profiling assays in breast cancer: are we ready for prime time? Oncology 2012;26:350-7.
4. Vladislav T, Jain RK, Alvarez R, Mehta RJ, Gökmen-Polar Y, Kesler KA, Henley JD, LoehrerSr PJ, Badve S. Extrathoracic metastasis of thymic origin: a review of 35 cases. Mod Pathol2011 Nov 11[Epub ahead of print].
5. Gökmen-Polar Y, Nakshatri H, Badve S. Biomarkers for breast cancer stem cells: the challenges ahead. Biomark Med. 2011 Oct;5(5):661-71.
6. Gökmen-Polar Y, Badve S. Tumor marker assessment: points to ponder. Cancer BiolTher2011;11:284-6
7. Gökmen-Polar Y, Toroni RA, Hocevar BA, Badve S, Zhao Q, Shen C, Bruckheimer E, Kinch MS, Miller KD. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res Treat. 2011 Jun;127(2):375-84 [Epub ahead of print Jul 3].
8. Gökmen-Polar Y*, Mehta R, TuzmenS, Mousses S, Thorat MA, Sanders KL, Turbin D, Leung S, Huntsman DG, Sledge GW Jr, Badve S*. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.Breast Cancer Res Treat. 2010 Nov;124(2):327-35 [Epub ahead of print Jan 23]. (* corresponding authors)
9. Brown DPG, Gökmen-Polar Y, Jiang L, Tan J, Ringham H, Janecki DJ, Qi G, Witzmann FA, Sledge GW Jr, Wang M.  A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells.  Proteomics 2007;1:18-31.
10. Bhati R, Gökmen-Polar Y, Sledge GW Jr,Fan C, Nakshatri H,Ketelsen D, Borchers CH, Dial MJ, Patterson C, Klauber-DeMore N.  2-methoxyestradiol inhibits the anaphase promoting complex and protein translation in human breast cancer cells.  Cancer Res 2007;67:702-8.
11. Shanmugam R, Jayaprakasan V, Gökmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, Degrado T, Hutchins GD, Sweeney CJ.  Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate 2006;66:1498-511.
12. Gökmen-Polar Y *, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, LaVallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW Jr.  β-tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res 2005;65:9406-14 (* corresponding author).
13. Murray NR, Jamieson L, YU W, Zhang J, Gökmen-Polar Y, Sier D, Anastasiadis P, Gatalica Z, Thompson EA, and Fields, AP.  Protein kinase C iota is required for Ras transformation and colon carcinogenesis in vivo. J Cell Biol 2004;164:797-802.
14. Lu M, Miller KD, Gökmen-Polar Y, Jeng MH, Kinch MS.  EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.  Cancer Res 2003;63:3425-9.
15. Gökmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP.  Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis.  Cancer Res 2001;61:1375-81.
16. Gökmen-Polar Y, Fields AP.  Mapping of a molecular determinant for protein kinase C beta II isozyme function.  J BiolChem1998;273:20261-6.